Howe & Rusling Inc. Has $486,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Howe & Rusling Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 462 shares of the biopharmaceutical company’s stock after purchasing an additional 15 shares during the period. Howe & Rusling Inc.’s holdings in Regeneron Pharmaceuticals were worth $486,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of REGN. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC raised its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $28,000. Finally, Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $743.35 on Thursday. The company has a market capitalization of $81.69 billion, a price-to-earnings ratio of 18.40, a PEG ratio of 2.81 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $736.01 and a twelve month high of $1,211.20. The stock has a fifty day simple moving average of $961.76 and a 200 day simple moving average of $1,030.14.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on REGN. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.